Single-cell penile cancer atlas to identify disease drivers

Maria Chiara Masone

DOI: https://doi.org/10.1038/s41585-024-00909-4

2024-06-15

Nature Reviews Urology

Abstract:Penile squamous cell carcinoma (PSCC) can be classified into human papilloma virus-positive (HPV + ) and HPV-independent (HPV – ). HPV + tumours have higher rates of poorly differentiated disease than HPV – tumours. However, a lower cancer-specific mortality (CSM) has been reported in patients with HPV + versus HPV – disease. This evidence might be partially explained by a disproportionate occurrence of loss-of-function mutations of TP53 ( TP53 LOF) in patients with HPV – versus HPV + disease. In a study published in European Urology , a PSCC single-cell RNA sequencing (scRNA-seq) atlas was established to identify molecular characteristics that might explain prognostic differences observed between patients with HPV + and HPV – tumours. scRNA-seq and T cell receptor sequencing were carried out in 16 fresh tumour samples from patients with treatment-naive primary PSCC and 6 non-malignant inner prepuce samples. A total of four groups were defined based on HPV and TP53 status: normal ( n = 6), HPV + TP53 wild-type (WT; n = 6), HPV – TP53 WT ( n = 6) and TP53 LOF (irrespective of HPV status; n = 4). Analysis of CSM of patients from an independent international cohort validated the prognostic relevance of these groups, with patients with TP53 -mutated tumours having a significantly worse prognosis than patients with TP53 WT tumours ( P = 0.002). Results from the scRNA-seq analysis showed that TP53 LOF tumours had an aggressive phenotype characterized by gene signatures of epithelial-to-mesenchymal transition, angiogenesis and immune exclusion. HPV – TP53 WT tumours showed immune exhaustion, whereas HPV + TP53 WT tumours showed a normal epithelial maturation and an upregulation of multiple antibody–drug conjugate targets, suggesting a potential therapeutic utility.

urology & nephrology